secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001737287-24-000055
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allogene Q2 net loss $66.4M ($0.35/sh); initiated pivotal ALPHA3 trial for cema-cel
--------------------------------------------------------------------------------

- Net loss of $66.4M ($0.35 per share) includes $13.6M stock-based comp and $5.0M impairment.
- Cash, equivalents and investments $444.6M as of June 30, 2024; runway into 2H 2026.
- Pivotal Phase 2 ALPHA3 trial for cema-cel in 1L LBCL initiated; enrollment completion expected 1H 2026, BLA submission 2027.
- ALLO-329 (CD19/CD70 dual CAR) IND on track for Q1 2025 in autoimmune disease; proof-of-concept by YE 2025.
- ALLO-316 Phase 1 TRAVERSE data update with ~20 RCC patients planned for YE 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000173728724000055/0001737287-24-000055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000173728724000055/allo-20240807.htm
  HTML page:      https://secwatch.observer/filing/0001737287-24-000055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer